Analyst Price Targets — CLDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 10:58 am | — | Barclays | $24.00 | $26.68 | TheFly | Celldex price target raised to $24 from $21 at Barclays |
| November 11, 2025 10:24 am | — | Barclays | $21.00 | $22.67 | TheFly | Celldex price target lowered to $21 from $25 at Barclays |
| October 13, 2025 9:27 am | — | Barclays | $25.00 | $26.77 | TheFly | Celldex initiated with an Underweight at Barclays |
| March 20, 2025 7:51 am | — | Morgan Stanley | $46.00 | $19.88 | TheFly | Celldex initiated with an Overweight at Morgan Stanley |
| October 29, 2024 7:25 am | Joseph Pantginis | H.C. Wainwright | $80.00 | $27.12 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX) |
| September 25, 2024 3:10 pm | Derek Archila | Wells Fargo | $44.00 | $36.02 | TheFly | Celldex upgraded to Overweight from Equal Weight at Wells Fargo |
| June 17, 2024 4:15 pm | Alex Thompson | Stifel Nicolaus | $58.00 | $34.91 | TheFly | Celldex initiated with a Buy at Stifel |
| November 10, 2023 5:05 am | Derek Archila | Wells Fargo | $27.00 | $25.78 | StreetInsider | Wells Fargo Upgrades Celldex Therapeutics (CLDX) to Equal Weight |
| November 11, 2022 8:51 am | — | Guggenheim | $63.00 | $39.89 | Benzinga | Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63 |
Latest News for CLDX
Celldex Therapeutics (NASDAQ: CLDX) executives used an appearance at H.C. Wainwright's annual Inflammation and Skin Disease Conference to highlight the company's late-stage plans for barzolvolimab, an anti-KIT monoclonal antibody being developed for chronic urticaria and other inflammatory skin diseases, and to outline upcoming clinical milestones across the pipeline. Barzolvolimab positioned as mast-cell depleting…
HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference on Tuesday, April 14 at 3:30 pm ET.
SG Americas Securities LLC grew its position in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 143.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 47,340 shares of the biopharmaceutical company's stock after purchasing an additional 27,872 shares during
HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 11,896,750 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,551,750 shares of common stock at a public offering price of $29.00 per…
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares to be sold in the offering are to be sold by Celldex. In connection with the offering, Celldex has also granted the underwriters…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLDX.
U.S. House Trading
No House trades found for CLDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.